Drug Type Small molecule drug |
Synonyms Occlusin 500 Artificial Embolization Device, Occlusin 500 Device, Tactin + [1] |
Target- |
Action stimulants |
Mechanism Platelet aggregation stimulants |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Liver Cancer | Phase 1 | Canada | 31 Mar 2005 | |
Leiomyoma | Phase 1 | Canada | 30 Mar 2004 |
Not Applicable | 34 | (Men with metastatic prostate cancer) | nkpckqdzia(usngsxwbit) = qwgvwgvmll wohawibedt (sznpvmlekl ) View more | - | 26 Feb 2018 | ||
Not Applicable | 583 | (Cohort A (2004-2007)) | (zjxummopgx): HR = 0.69 (95% CI, 0.57 - 0.83) | Positive | 26 Feb 2018 | ||
(Cohort B (2010-2013)) |